Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders

M Tokuhira, J Tamaru, M Kizaki - Journal of clinical and experimental …, 2019 - jstage.jst.go.jp
… Similar to P-LPD, chemotherapy for such aggressive cases is based on the diagnosis of
similar pathological features in M-LPD (described in the MTX-ND-LPD section). However, the …

Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with …

…, H Ogawa, N Sekiguchi, H Takei, M Tokuhira… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: Acute/subacute interstitial pneumonia (A/SIP) in patients with polymyositis/dermatomyositis
(PM/DM) is frequently fatal within months despite high dose prednisolone (PSL) …

RANTES expression and contribution to monocyte chemotaxis in arthritis

MV Volin, MR Shah, M Tokuhira, GK Haines III… - Clinical immunology and …, 1998 - Elsevier
Rheumatoid arthritis (RA) is characterized by recruitment of leukocytes from the vasculature
into inflamed synovial tissue (ST) and synovial fluid (SF), which depends, in part, upon the …

Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors

…, K Nagafuji, J Tamaru, M Tokuhira… - The American Journal …, 2019 - journals.lww.com
Methotrexate (MTX) carries a risk of lymphoproliferative disorders (LPDs), but MTX-associated
LPDs (MTX-LPDs) can resolve spontaneously after MTX withdrawal. However, the …

[HTML][HTML] Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

…, C Ohwada, J Kuroki, H Kimura, M Tokuhira… - …, 2018 - ncbi.nlm.nih.gov
The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with
nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic …

Massive pericardial effusion in scleroderma: a review of five cases

M Satoh, M Tokuhira, N Hama, M Hirakata… - …, 1995 - academic.oup.com
Medical records of five patients with sclerodenna (SSc), each of whom had pericardial effusion
with an estimated volume of more than 200 ml, were reviewed to study the clinical and …

Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression

M Tokuhira, S Saito, A Okuyama, K Suzuki… - Leukemia & …, 2018 - Taylor & Francis
Although recent accumulative data reveal the clinicopathogenesis of regression in
methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding …

Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis

M Tokuhira, R Watanabe, T Nemoto… - Leukemia & …, 2012 - Taylor & Francis
Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated
lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly …

Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate

S Saito, Y Kaneko, K Yamaoka, M Tokuhira… - …, 2017 - academic.oup.com
Objective. To clarify the characteristics of lymphoproliferative disorder (LPD) in patients with
RA treated with MTX. Methods. Among 33 patients developing LPD during MTX treatment, …

[HTML][HTML] Critical residues of integrin αIIb subunit for binding of αIIbβ3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3)

T Kamata, A Irie, M Tokuhira, Y Takada - Journal of Biological Chemistry, 1996 - ASBMB
Integrin αIIbβ3 plays a critical role in platelet aggregation through its interaction with fibrinogen.
Elucidation of the mechanisms of αIIbβ3-fibrinogen interaction is critical to understanding …